Alnylam Pharmaceuticals (NASDAQ:ALNY) Announces Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03), Zacks reports. Alnylam Pharmaceuticals updated its FY 2025 guidance to EPS.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded down $1.78 during trading hours on Thursday, reaching $264.19. The stock had a trading volume of 296,789 shares, compared to its average volume of 663,343. The stock has a market cap of $34.07 billion, a P/E ratio of -100.90 and a beta of 0.35. The stock has a 50 day simple moving average of $253.77 and a 200 day simple moving average of $262.99. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39.

Insider Activity

In other news, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the transaction, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,964 shares of company stock valued at $20,622,925 in the last 90 days. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ALNY. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday. Piper Sandler restated an “overweight” rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, Barclays upped their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.